RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY

Autor:	Luc Xerri, J.C. Eisenmann, T. Lamy de la Chapelle, H. Tilly, Vincent Ribrag, Loic Ysebaert, Gilles Salles, Hervé Maisonneuve, Corinne Haioun, H. Jardel, Pierre Feugier, M.H. Delfau-Larue, F. Morschhauser, G. Cartron, M.L. Boulland, Thierry Fest, Sylvie Glaisner, Olivier Casasnovas, S. Le Gouil, G.M. Pica
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Follicular lymphoma Molecular Disease Ancillary Study Hematology General Medicine medicine.disease Internal medicine Medicine Rituximab business medicine.drug Lenalidomide
Zdroj:	Hematological Oncology. 37:117-118
ISSN:	0278-0232
DOI:	10.1002/hon.77_2629
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9b56dd4db0bb04ae58778517e98934f1 https://doi.org/10.1002/hon.77_2629 Zobrazit plný text záznamu Plný text